Skip to content
OpenCapital
Get started

Xilio Therapeutics, Inc. XLO Q2 2025 earnings

Reported August 14, 2025 · Before market open

Revenue$8.1MMiss by $10.6MDiluted EPS-$0.16Beat by $0.94
Revenue estimate$18.6M
EPS estimate-$1.10

Next report

Aug 13, 2026 (in a month)
Revenue estimate$12.7M
EPS estimate-$0.59

Versus estimates

Revenue

Q1 2026$12.7MBeat by $4.1MQ4 2025$13.7MBeat by $2.8MQ3 2025$19.1MBeat by $431.0K
Q2 2025$8.1MMiss by $10.6M
Q1 2025$2.9MMiss by $20.3MQ4 2024$1.7MMiss by $21.5M

Diluted EPS

Q1 2026-$0.58Beat by $0.08Q4 2025-$0.85Beat by $0.83Q3 2025-$0.03Beat by $0.42
Q2 2025-$0.16Beat by $0.94
Q1 2025-$0.18Beat by $2.52Q4 2024-$0.20Beat by $2.83

Ask the moment Xilio Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Xilio Therapeutics, Inc. report Q2 2025 earnings?
Xilio Therapeutics, Inc. (XLO) reported Q2 2025 earnings on August 14, 2025 before market open.
What were Xilio Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Xilio Therapeutics, Inc. reported revenue of $8.1M and diluted EPS of $-0.16 for Q2 2025.
Did Xilio Therapeutics, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $18.6M by $10.6M. EPS beat the consensus estimate of $-1.10 by $0.94.
How did Xilio Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 243.0% from $2.4M a year earlier and diluted EPS grew 33.3% from $-0.24.
Where can I find Xilio Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001558370-25-011477) directly on SEC EDGAR. The filing index links above go to sec.gov.